<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211457</url>
  </required_header>
  <id_info>
    <org_study_id>CYC682-11</org_study_id>
    <nct_id>NCT01211457</nct_id>
  </id_info>
  <brief_title>Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)</brief_title>
  <official_title>A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclacel Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cyclacel Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a combination study to evaluate sapacitabine administered in alternating cycles with
      decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with
      venetoclax in previously treated AML or MDS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single arm, study of sapacitabine administered in alternating cycles
      with decitabine in elderly patients with previously untreated AML (Part 1) or concomitantly
      with venetoclax in adult patients with relapsed or refractory AML or MDS (Part 2). Treatment
      will be administered on an outpatient basis. One treatment cycle is 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2010</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who achieve a clinical benefit response including CR, CRp, PR and major HI</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response duration</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transfusion requirements</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalized days</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Sapacitabine/decitabine (Part 1 - completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>decitabine will be administered in alternating cycles with sapacitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sapacitabine/venetoclax (Part 2 - recruiting)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sapacitabine will be administered concomitantly with venetoclax</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine and decitabine (Part 1 - completed)</intervention_name>
    <description>decitabine will be administered in alternating cycles with sapacitabine</description>
    <arm_group_label>Sapacitabine/decitabine (Part 1 - completed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine and venetoclax (Part 2 - recruiting)</intervention_name>
    <description>sapacitabine will be administered concomitantly with venetoclax</description>
    <arm_group_label>sapacitabine/venetoclax (Part 2 - recruiting)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed AML based on WHO classification (Part 1) or previously treated AML or
             MDS (Part 2)

          -  Age 70 years or older for whom the treatment of choice is low-intensity therapy by
             investigator assessment or who has refused intensive induction therapy recommended by
             investigator (Part 1); age 18 years or older (Part 2)

          -  ECOG performance status 0-2

          -  Adequate renal function

          -  Adequate liver function

          -  Able to swallow capsules

          -  Ability to understand and willingness to sign the informed consent form

        Exclusion Criteria:

          -  AML is of the sub-type of acute promyelocytic leukemia or extramedullary myeloid tumor
             without bone marrow involvement

          -  Known central nervous system (CNS) involvement by leukemia

          -  Uncontrolled intercurrent illness including

          -  Known hypersensitivity to decitabine (Part 1) or venetoclax (Part 2)

          -  Known to be HIV-positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop M Kantarjian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy H Chiao, MD</last_name>
    <phone>9085177330</phone>
    <email>jchiao@cyclacel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3387</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Bull - Linderman, RN</last_name>
      <phone>713-563-4303</phone>
      <email>DLBull@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Tapan M Kadia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bloodjournal.org/content/120/21/2630/tab-article-info</url>
    <description>Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.</description>
  </link>
  <results_reference>
    <citation>Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Farhad Ravandi, Tapan M. Kadia, Gautam Borthakur, William G. Wierda, Stuart L. Goldberg, Meir Wetzler, Parameswaran Venugopal, Karen Seiter, Judy Chiao and Hagop M. Kantarjian. Blood 2012 120:2630.</citation>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sapacitabine</keyword>
  <keyword>decitabine</keyword>
  <keyword>venetoclax</keyword>
  <keyword>elderly</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>Refractory</keyword>
  <keyword>relapsed</keyword>
  <keyword>untreated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Sapacitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

